PDE5A and benign prostatic hyperplasia: The role of PDE5 inhibitors in the management of specific urethral dysfunctions has not been studied yet; therefore, it is difficult to determine whether and if the specific subset of BPH patients with urethral dysfunctions will benefit from the combination of PDE5-Is with agents commonly administered to benign prostatic hyperplasia.